<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Natalizumab (including biosimilars): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Natalizumab (including biosimilars): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Natalizumab (including biosimilars): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11990" href="/d/html/11990.html" rel="external">see "Natalizumab (including biosimilars): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709166"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal leukoencephalopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability.</p>
<p style="text-indent:-2em;margin-left:2em;">Risk factors for the development of PML include the presence of anti-JC virus antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with natalizumab.</p>
<p style="text-indent:-2em;margin-left:2em;">Health care professionals should monitor patients on natalizumab for any new sign or symptom that may be suggestive of PML. Natalizumab dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of PML, natalizumab is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) called the TOUCH prescribing program.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F200027"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tysabri</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867651"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tysabri</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F200046"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gastrointestinal Agent, Miscellaneous;</li>
<li>
                        Monoclonal Antibody, Selective Adhesion-Molecule Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F200029"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease (alternative agent): Note:</b> Not recommended for routine use due to the risk of progressive multifocal leukoencephalopathy (PML) and availability of other treatment options; may consider use if the benefits of use outweigh the risks in patients who are JC virus antibody-negative and who agree to regular screening for JC virus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-34051983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-34051983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg infused over 1 hour every 4 weeks; discontinue if therapeutic benefit is not observed within initial 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34051983','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34051983','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Concomitant use with corticosteroids: </i>For patients who begin treatment while on chronic oral corticosteroids, begin tapering oral steroids when the onset of natalizumab therapeutic benefit is observed; discontinue use if patient cannot be tapered off of oral corticosteroids within 6 months of therapy initiation. If additional concomitant corticosteroids are required and exceed 3 months/year (in addition to initial corticosteroid taper), consider discontinuing therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b>
<b>Note: </b>In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>). In patients with anti-John Cunningham Virus (JCV) antibodies, consider switching to a disease-modifying therapy with lower risk of progressive multifocal leukoencephalopathy (PML), especially if anti-JCV antibody index &gt;0.9 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29686116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29686116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg infused over 1 hour every 4 weeks; guidelines suggest limiting duration of therapy to 24 months unless benefits outweigh risks of PML (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29686116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29686116'])">Ref</a></span>). <b>Note: </b>Limited evidence suggests extended interval infusion (administration every 5 to 8 weeks) may be associated with a lower risk of PML and similar efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31452081','lexi-content-ref-35223079','lexi-content-ref-26917698','lexi-content-ref-31515290','lexi-content-ref-29982107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31452081','lexi-content-ref-35223079','lexi-content-ref-26917698','lexi-content-ref-31515290','lexi-content-ref-29982107'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991591"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988781"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Discontinue use with jaundice or signs/symptoms of hepatic injury.</p></div>
<div class="block doe drugH1Div" id="F200030"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F200003"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (11%), gastroenteritis (11%; cryptosporidial gastroenteritis: &lt;1%), nausea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (3% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (19%), fatigue (10% to 27%), headache (32% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (8% to 19%), back pain (12%), limb pain (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (5% to 11%), lower respiratory tract infection (17%), upper respiratory tract infection (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (11% to 24%; severe infusion related reaction: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (5%), peripheral edema (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (7%), night sweats (1%), pruritus (4%), urticaria (2%), xeroderma (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (2%), menstrual disease (5%), ovarian cyst (2%), weight changes (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis (2%), cholelithiasis (≤1%), constipation (4%), diarrhea (10%), dyspepsia (5%), flatulence (3%), gastrointestinal stenosis (≤2%), intestinal obstruction (≤2%), lower abdominal pain (4%), tooth infection (9%), toothache (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (2% to 6%), urinary frequency (≤9%), urinary incontinence (4%), urinary urgency (≤9%), vaginal infection (4% to 8%), vaginitis (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (5%, including increased serum bilirubin, increased serum transaminases)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (acute: 2% to 4%; serious acute: ≤1%; delayed: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (9% to 10%; antibodies correlated with a reduction in serum natalizumab levels; persistent antibody-positivity resulted in a decrease in effectiveness)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection (8%), serious infection (2% to 3%) viral infection (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (2%), rigors (3%), vertigo (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling (2%), muscle cramps (5%), tremor (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3% to 7%), pharyngolaryngeal pain (6%), sinusitis (8%), tonsillitis (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Appendicitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (mild, transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal septicemia (cryptococcal), opportunistic infection (including aspergillosis [bronchopulmonary], infection [Burkholderia cepacian], pneumonia caused by <i>Pneumocystis jirovecii</i>, pulmonary infection [Mycobacterium avium intracellulare])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Meningitis (including cryptococcal meningitis), progressive multifocal leukoencephalopathy, suicidal ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (including Candida pneumonia)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Basophilia, eosinophilia, lymphocytosis, monocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pericarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19414731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19414731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, thrombocytopenia (including immune thrombocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (including acute hepatic failure)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immune reconstitution syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: JC virus infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalitis (varicella zoster), herpes simplex encephalitis, meningitis (herpes simplex and varicella zoster)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinopathy (acute retinal necrosis)</p></div>
<div class="block coi drugH1Div" id="F200016"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to natalizumab or any component of the formulation; current or history of progressive multifocal leukoencephalopathy (PML)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Immunocompromised patients as a result of immunosuppressant or antineoplastic therapy, or immunodeficiencies (eg, HIV, leukemia, lymphoma)</p></div>
<div class="block war drugH1Div" id="F200001"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity, including acute liver failure requiring transplant, has been reported with use. Signs of hepatotoxicity, including transaminase and bilirubin elevation occurred as early as 6 days after the first dose or following multiple doses; may recur with treatment rechallenge; discontinue use with jaundice or signs/symptoms of hepatic injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Herpes infection: Serious, life-threatening herpes infections, including fatalities (herpes encephalitis or herpes meningitis infections caused by herpes simplex and varicella zoster viruses) have occurred within a few months to several years of natalizumab treatment. Monitor patients for signs/symptoms of meningitis and encephalitis. In the presence of herpes encephalitis or meningitis, discontinue therapy. Acute retinal necrosis (ARN), a fulminant viral infection of the retina caused by the family of herpes viruses (eg, varicella zoster, herpes simplex virus) has also been observed during natalizumab treatment. Some cases occurred in patients with CNS herpes infections (eg, herpes meningitis, encephalitis); serious cases may result in blindness. Following diagnosis of ARN, consider discontinuation of natalizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/antibody formation: Hypersensitivity reactions including serious systemic reactions (eg, anaphylaxis) have occurred in &lt;1% of patients. Symptoms may include dizziness, fever, flushing, rigors, hypotension, dyspnea, chest pain, nausea, pruritus, rash, and urticaria and typically occur within 2 hours of starting the infusion. Reactions are generally associated with antibodies to natalizumab; consider the possibility of antibodies in patients who have hypersensitivity reactions. Patients with an extended interruption in therapy following a short exposure (1 to 2 infusions) to natalizumab may be at an increased risk for developing anti-natalizumab antibodies and/or hypersensitivity reactions following reinitiation of therapy. If a hypersensitivity reaction occurs, discontinue use; patients who have developed hypersensitivity reactions should not be re-treated. Antibody formation (which occurs in about 10% of patients) is associated with a decrease in natalizumab levels and a decrease in the efficacy of natalizumab. Antibody testing should be performed in any patient when there is a suspicion of persistent antibodies and should be considered in patients that resume therapy following a period of dosage interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution inflammatory syndrome (IRIS): IRIS has been reported in patients after discontinuing natalizumab due to PML. In most cases, this occurred within days to weeks after plasma exchange was used in an attempt to remove natalizumab. IRIS is a rare condition which is characterized by severe inflammation during or following immune system recovery, which can result in a decline in patient condition, including neurological symptoms and death.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Use may be associated with an increased risk of infections, including opportunistic infections and serious herpes infections (rare, postmarketing reports; concurrent use of antineoplastic, immunosuppressant [including short-course corticosteroids], or immunomodulating agents may increase this risk); discontinue therapy until successful resolution of the infection. When using for the treatment of multiple sclerosis in high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lab test abnormalities: Reversible increases in circulating lymphocytes, monocytes, eosinophils, basophils, and nucleated red blood cells may occur; changes persist during natalizumab exposure but usually return to baseline within 16 weeks after the last dose. Mild transient decreases in hemoglobin levels may also occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Monitor for any new signs/symptoms suggestive of PML; immediately withhold treatment at the first sign or symptom suggesting PML. For diagnosis of PML, an evaluation should include a gadolinium-enhanced MRI scan of the brain and (if indicated) analysis of CSF for John Cunningham Virus (JCV) DNA. Retrospective analyses suggest risk of developing PML may be associated with relative serum anti-JCV antibody levels compared to a calibrator as measured by ELISA. Cases of PML have been diagnosed based on MRI findings and the detection of JCV DNA in the CSF without specific PML signs/symptoms (including progressive weakness on one side of the body, limb clumsiness, visual disturbance, changes in thinking, memory, personality or orientation) reported. Use should ordinarily be avoided in patients who are significantly immunocompromised or receiving chronic immunosuppressant or immunomodulatory therapy. For an early diagnosis of PML, consider periodic monitoring with an MRI scan for radiographic signs of PML. Anti-JCV antibody testing prior to or during treatment may be considered; testing should not be used to diagnose PML and should not be performed for at least 2 weeks after plasma exchange. Patients who are anti-JCV antibody negative are still at risk for developing PML, although the risk is lower; therefore, patients with a negative anti-JCV antibody test result should be retested periodically. A brain MRI scan (baseline) should be obtained prior to initiating therapy in MS patients and should be considered in patients with Crohn disease. PML has also been reported following discontinuation in patients who did not have findings suggestive of PML at the time of discontinuation; patients should be monitored for signs and symptoms of PML for at least 6 months after discontinuation of therapy. Extended interval dosing (infusions every 5 to 6 weeks instead of every 4 weeks) may be associated with a lower PML risk (Ryerson 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Cases of thrombocytopenia, including immune thrombocytopenic purpura, have been reported; symptoms may include easy bruising, abnormal bleeding, and petechiae. Delayed diagnosis and treatment may lead to serious and life-threatening sequelae; discontinue use if thrombocytopenia is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Crohn disease: Natalizumab should not be used in combination with immunosuppressants or tumor necrosis factor inhibitors in patients with Crohn disease; aminosalicylates may be used concurrently with natalizumab. For patients who begin treatment while on chronic oral corticosteroids, begin tapering oral steroids when the onset of natalizumab therapeutic benefit is observed; discontinue use if patient cannot be tapered off of oral corticosteroids within 6 months of therapy initiation. If additional concomitant corticosteroids are required and exceed 3 months/year (in addition to initial corticosteroid taper), consider discontinuing therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use should be restricted to patients with inadequate response to or intolerant of other therapies for Crohn disease or multiple sclerosis. Carefully evaluate the overall benefit to risk in patients that develop persistent antibodies to natalizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Cases of rebound syndrome (clinical and radiological signs of severe exacerbation beyond what was expected) have been reported; may occur within the first 24 weeks after stopping natalizumab treatment in patients with multiple sclerosis of varying severity and duration. In some cases, relapses have occurred despite the initiation of other disease-modifying therapies. Patients who experience rebound symptoms may not return to the functional status attained during treatment with natalizumab. Monitor for development of severe increase in disability, especially during the first 12 weeks following discontinuation and begin appropriate treatment as needed. Initiating fingolimod within 12 weeks after discontinuation of natalizumab may prevent relapse (AAN [Rae-Grant 2018]; Clerico 2017; Sellner 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: There are no data available concerning the effect of vaccination or secondary transmission of infection by live vaccines in patients receiving natalizumab. When using for the treatment of multiple sclerosis, avoid live-attenuated vaccines in patients who currently receive or have recently discontinued natalizumab; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: <b>[US Boxed Warning]: Access is restricted through a REMS program called the TOUCH Prescribing Program;</b> prescribers and pharmacies must be certified with the Tysabri Outreach Unified Commitment to Health (TOUCH) Prescribing Program. Patients must also be enrolled in the TOUCH Prescribing Program (800-456-2255) to receive natalizumab (MS-TOUCH for multiple sclerosis or CD-TOUCH for Crohn disease).</p></div>
<div class="block prod-avail drugH1Div" id="F58599658"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Tyruko: FDA approved August 2023; anticipated availability currently unknown. Tyruko is approved as biosimilar to Tysabri. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F200011"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tysabri: 300 mg/15 mL (15 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F199999"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323460"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Tysabri Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/15 mL (per mL): $656.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867652"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tysabri: 300 mg/15 mL (15 mL) [contains polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F11234120"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">
<b>Canada:</b> Natalizumab is only available through a controlled distribution program called Biogen ONE Support Program (855-676-6300 or https://www.BiogenTherapies.ca). This program is associated with the prescribing, administration, and monitoring of Canadian patients receiving natalizumab. Clinicians are educated on the appropriate use of natalizumab and are expected to discuss the benefits/risks of therapy. Clinicians should evaluate patients every 6 months during treatment. Under this program, only prescribers and pharmacies registered with the program are able to prescribe and dispense natalizumab. In addition, natalizumab can only be dispensed to patients who are registered and meet all the conditions of the Biogen ONE Support Program.</p></div>
<div class="block adm drugH1Div" id="F200013"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">If stored under refrigeration, allow solution to warm to room temperature prior to administration. Diluted solution should be infused over 1 hour; do not administer by IV bolus or push. Patients should be closely monitored for signs and symptoms of hypersensitivity during all infusions. For the first 12 infusions, observe patients post-infusion or at least 1 hour after the infusion is complete; patients who have received 12 infusions without evidence of hypersensitivity may be observed post-infusion using clinical judgement for subsequent infusions. The infusion should be discontinued if a reaction occurs, and treatment of the reaction should be instituted. Following infusion, flush line with NS.</p></div>
<div class="block meg drugH1Div" id="F7885623"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125104s976s979lbl.pdf%23page%3D32&amp;token=ZkirY0Y8o4Qu1B4LRUwvFTtMCwdVBAO2HF9kuQaumaLH2a1RmRqRHahjlo91nD6MVDVD6nM%2Fblf9mjFlRituFfUItEMvi67%2FI7WIW3kNunnU7RQsSggb%2Bzw1KHPbcDUD&amp;TOPIC_ID=10252" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125104s976s979lbl.pdf#page=32</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F200012"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease:</b> Inducing and maintaining clinical response and remission in adults with moderately to severely active Crohn disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn disease therapies and inhibitors of tumor necrosis factor-alpha (TNF-alpha).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b> As monotherapy for the treatment of patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Natalizumab increases the risk of progressive multifocal leukoencephalopathy. When initiating and continuing treatment with natalizumab, consider whether the expected benefit of natalizumab is sufficient to offset this risk.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Treatment of relapsing forms of multiple sclerosis in patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.</p></div>
<div class="block cyt drugH1Div" id="F13299746"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F200005"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Natalizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the immunosuppressive effect of Natalizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the immunosuppressive effect of Natalizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Natalizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferon Beta-1a: May enhance the adverse/toxic effect of Natalizumab. Specifically, the risk for progressive multifocal leukoencephalopathy (PML) may be increased. Interferon Beta-1a may increase the serum concentration of Natalizumab. Management: Consider alternatives to this combination whenever possible. Combined use may increase the risk for progressive multifocal leukoencephalopathy (PML).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Natalizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab: May enhance the adverse/toxic effect of Natalizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53464386"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy except in patients at high risk of MS activity (AAN [Rae-Grant 2018]). Consider use of agents other than natalizumab for patients at high risk of disease reactivation who are planning to become pregnant (ECTRIMS/EAN [Montalban 2018]). Delaying pregnancy is recommended for patients with persistent high disease activity; however, when disease-modifying therapy is needed in these patients, natalizumab may be continued following a full discussion of potential risks (ECTRIMS/EAN [Montalban 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Clinical rebound (new neurologic symptoms and increased lesions) has been reported when natalizumab was discontinued prior to pregnancy, resulting in permanent disability is some patients. Continuing treatment until pregnancy is confirmed and through the first trimester, then restarting soon after delivery may prevent relapse in high-risk patients (Demortiere 2021; Hellwig 2022; Hradilek 2022; Kleerekooper 2017; Portaccio 2018b; Vukusic 2015; Yeh 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes; maternal disease and serum levels of biologic therapy should be optimized prior to conception. Biologics, such as natalizumab, may be continued in patients with inflammatory bowel disease planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning to become pregnant (Weizman 2019).</p></div>
<div class="block pri drugH1Div" id="F200018"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Natalizumab crosses the placenta (Haghikia 2014; Proschmann 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Natalizumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data related to the use of natalizumab in pregnancy are available from pregnancy registries and systematic reviews in which most patients discontinued use once pregnancy was detected (Ebrahimi 2015; Friend 2016; Peng 2019; Portaccio 2018a; Portaccio 2022). Hematological abnormalities in the newborn, such as anemia and thrombocytopenia, have been noted following maternal use during the third trimester (Haghikia 2014; Proschmann 2018; Triplett 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of natalizumab may be altered, resulting in decreased trough concentrations as pregnancy progresses (especially in extended-interval dosing [6 weeks]) but returning to baseline postpartum (Toorop 2022).</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in patients at high risk of MS activity (AAN [Rae-Grant 2018]). Clinical rebound (new neurologic symptoms and increased lesions) has been reported when natalizumab was discontinued prior to or during pregnancy, resulting in permanent disability in some patients. Continuing treatment until pregnancy is confirmed and through the first trimester and then restarting soon after delivery may prevent relapse in high-risk patients (Demortiere 2021; Hellwig 2022; Hradilek 2022; Kleerekooper 2017; Portaccio 2018b; Vukusic 2015; Yeh 2021). When disease-modifying therapy is needed in patients at high risk for relapse, natalizumab may be continued during pregnancy following a full discussion of potential risks (ECTRIMS/ EAN [Montalban 2018]). The last dose should be given ~34 to 40 weeks' gestation to minimize fetal exposure. The postpartum dose should be restarted within 8 to 12 weeks to prevent disease relapse (Dobson 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low birth weight infant, and poor maternal weight gain. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes. When treatment for inflammatory bowel disease is needed in pregnant patients, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For natalizumab, the final injection can be given 4 to 6 weeks prior to the estimated date of delivery, then continued 48 hours' postpartum (Mahadevan 2019).</p></div>
<div class="block brc drugH1Div" id="F200019"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations of natalizumab were evaluated in a lactating female, 11.5 months postpartum, who was breastfeeding her infant three times daily. Breast milk was sampled prior to and for 50 days following maternal administration of natalizumab 300 mg IV over 1 hour every 4 weeks. Breast milk concentrations of natalizumab were below the limit of detection for 13 days following the first dose and were variable until day 28 (second infusion administered on day 29). The highest breast milk concentration was observed on the last day of the study (day 50). Maternal plasma steady-state concentrations were not reached during the study period (Baker 2015). In a second study, breast milk concentrations of natalizumab were evaluated in four lactating females who had received between 9 and 55 doses of natalizumab prior to and during pregnancy. Breast milk was sampled for up to 145 days postpartum. Breast milk concentrations were highly variable but significantly correlated to the time since last infusion (Proschmann 2018). In a study of two women, only one had detectable breast milk concentrations; maximum concentrations occurred 24 hours after the infusion (Matro 2018). Limited data are available from a study of 17 lactating patients who received natalizumab during pregnancy and postpartum. Trace amounts of natalizumab were present in the breast milk of 3 mothers who provided samples. Natalizumab was not present in the serum of 2 of the breastfed infants tested. Two infants exposed to natalizumab via breast milk but not during the third trimester of pregnancy had normal CBCs (Ciplea 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Based on the limited data, recommendations related to natalizumab and breastfeeding vary (Almas 2016; Dobson 2019; Fragoso 2018). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F200009"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Symptoms of hepatotoxicity (eg, elevated serum transaminases, bilirubin) consider baseline and periodic monitoring; hypersensitivity reactions during, and for 1 hour after, infusion; symptoms of persistent anti-natalizumab antibody-positivity (eg, anxiety, dizziness, dyspnea, feeling cold, flushing, headache, hypertension, myalgia, nausea, pruritus, pyrexia, rigors, tachycardia, tremor, urticaria or, vomiting); signs/symptoms of meningitis and encephalitis; signs/symptoms of acute retinal necrosis; when using for the treatment of multiple sclerosis, latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline).</p>
<p style="text-indent:-2em;margin-left:2em;">Progressive multifocal leukoencephalopathy (PML): Monitor for signs and symptoms of PML (eg, weakness in one side of the body, vision disturbance, changes in memory or thinking) during treatment and for 6 months after discontinuation; also monitor for radiographic signs of PML periodically; anti-John Cunningham Virus (JCV) antibody testing is recommended prior to and periodically during therapy (patients who test positive for anti-JCV antibody at any time should be considered positive regardless of subsequent testing; periodically test patients who are anti-JCV antibody negative to ensure they remain negative). False-negative test for anti-JCV antibodies can occur in the setting of plasma exchange; wait at least 2 weeks after plasma exchange to test for anti-JCV antibodies. Intravenous immune globulin (IVIG) can produce a false positive for the presence of anti-JCV antibodies; wait at least 6 months after IVIG to verify anti-JCV antibody status.</p>
<p style="text-indent:-2em;margin-left:2em;">Baseline brain MRI scan; in patients with multiple sclerosis, additional MRI are generally recommended at 3 to 6 months, at 12 months, then annually (Wattjes 2021); consider more frequent MRI (eg, every 3 to 4 months) in patients at high risk of developing PML (Wattjes 2021); if PML is suspected, obtain gadolinium-enhanced brain MRI scan and CSF analysis for JCV DNA.</p>
<p style="text-indent:-2em;margin-left:2em;">Antibodies to natalizumab: Testing is recommended if persistent antibodies are suspected (if positive, repeat/confirm test in 3 months); consider antibody testing in patients that resume therapy following a period of dosage interruption.</p></div>
<div class="block pha drugH1Div" id="F200000"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Natalizumab is a monoclonal antibody against the alpha-4 subunit of integrin molecules. These molecules are important to adhesion and migration of cells from the vasculature into inflamed tissue. Natalizumab blocks integrin association with vascular receptors, limiting adhesion and transmigration of leukocytes. Efficacy in specific disorders may be related to reduction in specific inflammatory cell populations in target tissues. In multiple sclerosis, efficacy may be related to blockade of T-lymphocyte migration into the central nervous system; treatment results in a decreased frequency of relapse. In Crohn disease, natalizumab decreases inflammation by binding to alpha-4 integrin, blocking adhesion and migration of leukocytes in the gut. </p></div>
<div class="block phk drugH1Div" id="F200015"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Crohn disease: 2.4 to 8 L; Multiple sclerosis: 3.8 to 7.6 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Crohn disease: 3 to 17 days; Multiple sclerosis: 7 to 15 days </p></div>
<div class="block phksp drugH1Div" id="F51154884"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Antibodies: The presence of persistent anti-natalizumab antibodies increases natalizumab clearance approximately threefold.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: A less-than-proportional increase in clearance occurs as body weight increases, such that a 43% increase in body weight produces a 32% increase in clearance.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539898"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tysabri | Tysabri (300 mg Dose)</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Tysabri</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26966579">
<a name="26966579"></a>Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. <i>Mult Scler Int</i>. 2016;2016:6527458. doi: 10.1155/2016/6527458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/26966579/pubmed" id="26966579" target="_blank">26966579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25586712">
<a name="25586712"></a>Baker TE, Cooper SD, Kessler L, Hale TW. Transfer of natalizumab into breast milk in a mother with multiple sclerosis.<i> J Hum Lact</i>. 2015;31(2):233-6. doi: 10.1177/0890334414566237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/25586712/pubmed" id="25586712" target="_blank">25586712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22591293">
<a name="22591293"></a>Bloomgren G, Richman S, Hotermans C, et al, “Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy,” <i>N Engl J Med</i>, 2012, 366(20):1870-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/22591293/pubmed" id="22591293" target="_blank">22591293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32508210">
<a name="32508210"></a>Ciplea AI, Hellwig K. Exposure to natalizumab during pregnancy and lactation is safe - commentary. <i>Mult Scler</i>. 2020;26(8):892-893. doi:10.1177/1352458520928795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/32508210/pubmed" id="32508210" target="_blank">32508210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32327455">
<a name="32327455"></a>Ciplea AI, Langer-Gould A, de Vries A, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2020;7(4):e723. doi:10.1212/NXI.0000000000000723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/32327455/pubmed" id="32327455" target="_blank">32327455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28468254">
<a name="28468254"></a>Clerico M, Artusi CA, Liberto AD, et al. Natalizumab in multiple sclerosis: long-term management. <i>Int J Mol Sci</i>. 2017;18(5):940. doi: 10.3390/ijms18050940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/28468254/pubmed" id="28468254" target="_blank">28468254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31452081">
<a name="31452081"></a>Clerico M, De Mercanti SF, Signori A, et al. Extending the interval of natalizumab dosing: is efficacy preserved? <i>Neurotherapeutics</i>. 2020;17(1):200-207. doi: 10.1007/s13311-019-00776-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/31452081/pubmed" id="31452081" target="_blank">31452081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19414731">
<a name="19414731"></a>Cohen M, Rocher F, Brunschwig C, Lebrun C. Recurrent pericarditis due to natalizumab treatment. <i>Neurology</i>. 2009 May 5;72(18):1616-7. doi: 10.1212/WNL.0b013e3181a413aa.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/19414731/pubmed" id="19414731" target="_blank">19414731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32202216">
<a name="32202216"></a>Demortiere S, Rico A, Maarouf A, Boutiere C, Pelletier J, Audoin B. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. <i>Mult Scler</i>. 2021;27(5):712-718. doi:10.1177/1352458520912637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/32202216/pubmed" id="32202216" target="_blank">32202216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30612100">
<a name="30612100"></a>Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. <i>Pract Neurol</i>. 2019;19(2):106-114. doi: 10.1136/practneurol-2018-002060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/30612100/pubmed" id="30612100" target="_blank">30612100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25159275">
<a name="25159275"></a>Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. <i>Mult Scler</i>. 2015;21(2):198-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/25159275/pubmed" id="25159275" target="_blank">25159275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30167914">
<a name="30167914"></a>Fragoso YD, Adoni T, Brooks JBB, et al. Practical evidence-based recommendations for patients with multiple sclerosis who want to have children. <i>Neurol Ther</i>. 2018;7(2):207-232. doi: 10.1007/s40120-018-0110-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/30167914/pubmed" id="30167914" target="_blank">30167914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27552976">
<a name="27552976"></a>Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. <i>BMC Neurol</i>. 2016;16(1):150. doi: 10.1186/s12883-016-0674-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/27552976/pubmed" id="27552976" target="_blank">27552976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23899239">
<a name="23899239"></a>Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Rev Clin Immunol</i>. 2013;9(7):683-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/23899239/pubmed" id="23899239" target="_blank">23899239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12510039">
<a name="12510039"></a>Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for Active Crohn's Disease. <i>N Engl J Med.</i> 2003;348(1):24-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/12510039/pubmed" id="12510039" target="_blank">12510039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821217">
<a name="24821217"></a>Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. <i>JAMA Neurol</i>. 2014;71(7):891-895.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/24821217/pubmed" id="24821217" target="_blank">24821217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35072719">
<a name="35072719"></a>Hellwig K, Tokic M, Thiel S, et al. Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy. <i>JAMA Netw Open</i>. 2022;5(1):e2144750. doi:10.1001/jamanetworkopen.2021.44750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/35072719/pubmed" id="35072719" target="_blank">35072719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35240415">
<a name="35240415"></a>Hradilek P, Meluzinova E, Zapletalova O, et al. Is pregnancy in MS patients safe and what is its impact on MS course? Real world evidence of 1533 pregnancies in Czech Republic. <i>Mult Scler Relat Disord</i>. 2022;59:103391. doi:10.1016/j.msard.2021.103391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/35240415/pubmed" id="35240415" target="_blank">35240415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29379823">
<a name="29379823"></a>Kleerekooper I, van Kempen ZLE, Leurs CE, et al. Disease activity following pregnancy-related discontinuation of natalizumab in MS. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2017;5(1):e424. doi:10.1212/NXI.0000000000000424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29379823/pubmed" id="29379823" target="_blank">29379823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15167073">
<a name="15167073"></a>Koralnik IJ. New Insights Into Progressive Multifocal Leukoencephalopathy. <i>Curr Opin Neurol. </i>2004;17(3):365-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/15167073/pubmed" id="15167073" target="_blank">15167073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi: 10.1016/j.ajog.2019.02.027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35223079">
<a name="35223079"></a>McManus EJ, Clark KM, Frampton C, Macniven JAB, Schepel J. Extended interval dosing natalizumab and impact on neuropsychological deficits in relapsing-remitting multiple sclerosis. <i>Mult Scler J Exp Transl Clin</i>. 2022;8(1):20552173211070752. doi:10.1177/20552173211070752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/35223079/pubmed" id="35223079" target="_blank">35223079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi:10.1111/ene.13536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29857090">
<a name="29857090"></a>Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. <i>Gastroenterology</i>. 2018;155(3):696-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29857090/pubmed" id="29857090" target="_blank">29857090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30502611">
<a name="30502611"></a>Peng A, Qiu X, Zhang L, et al. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. <i>J Neurol Sci</i>. 2019;396:202-205. doi: 10.1016/j.jns.2018.11.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/30502611/pubmed" id="30502611" target="_blank">30502611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16510744">
<a name="16510744"></a>Polman CH, O’Connor PW, Havrdova E, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. <i>N Engl J Med.</i> 2006;354:899-910.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/16510744/pubmed" id="16510744" target="_blank">16510744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29438046">
<a name="29438046"></a>Portaccio E, Annovazzi P, Ghezzi A, et al; MS Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i>. 2018a;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29438046/pubmed" id="29438046" target="_blank">29438046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29438041">
<a name="29438041"></a>Portaccio E, Moiola L, Martinelli V, et al; MS Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i>. 2018b;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29438041/pubmed" id="29438041" target="_blank">29438041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35296189">
<a name="35296189"></a>Portaccio E, Pastò L, Razzolini L, et al. Natalizumab treatment and pregnancy in multiple sclerosis: a reappraisal of maternal and infant outcomes after 6 years. <i>Mult Scler</i>. 2022;28(13):2137-2141. doi:10.1177/13524585221079598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/35296189/pubmed" id="35296189" target="_blank">35296189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28857686">
<a name="28857686"></a>Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. <i>Mult Scler</i>. 2018;24(12):1627-1634. doi: 10.1177/1352458517728813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/28857686/pubmed" id="28857686" target="_blank">28857686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686116">
<a name="29686116"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29686116/pubmed" id="29686116" target="_blank">29686116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16510745">
<a name="16510745"></a>Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. <i>N Engl J Med.</i> 2006;354:911-923.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/16510745/pubmed" id="16510745" target="_blank">16510745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31515290">
<a name="31515290"></a>Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. <i>Neurology</i>. 2019;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/31515290/pubmed" id="31515290" target="_blank">31515290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26917698">
<a name="26917698"></a>Ryerson LZ, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. <i>J Neurol Neurosurg Psychiatry.</i> 2016;87(8):885-889. doi: 10.1136/jnnp-2015-312940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/26917698/pubmed" id="26917698" target="_blank">26917698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16267322">
<a name="16267322"></a>Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. <i>N Engl J Med.</i> 2005;353(18):1912-1925.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/16267322/pubmed" id="16267322" target="_blank">16267322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30639651">
<a name="30639651"></a>Sellner J, Rommer PS. A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis. <i>Autoimmun Rev</i>. 2019;18(3):255-261. doi: 10.1016/j.autrev.2018.09.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/30639651/pubmed" id="30639651" target="_blank">30639651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17484865">
<a name="17484865"></a>Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. <i>Gastroenterology.</i> 2007;132(5):1672-1683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/17484865/pubmed" id="17484865" target="_blank">17484865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34931887">
<a name="34931887"></a>Toorop AA, Rispens T, Strijbis EM, et al. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis. <i>Mult Scler</i>. 2022;28(2):323-326. doi:10.1177/13524585211052168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/34931887/pubmed" id="34931887" target="_blank">34931887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32028118">
<a name="32028118"></a>Triplett JD, Vijayan S, Rajanayagam S, Tuch P, Kermode AG. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. <i>Mult Scler Relat Disord</i>. 2020;40:101961. doi:10.1016/j.msard.2020.101961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/32028118/pubmed" id="32028118" target="_blank">32028118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tysabri.1">
<a name="Tysabri.1"></a>Tysabri (natalizumab) [prescribing information]. Cambridge, MA: Biogen Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tysabri.2">
<a name="Tysabri.2"></a>Tysabri (natalizumab) [product monograph]. Toronto, Ontario, Canada: Biogen Idec Canada Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15947080">
<a name="15947080"></a>Van Assche G, Van Ranst M, Sciot R, et al. Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease. <i>N Engl J Med.</i> 2005;353(4):362-368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/15947080/pubmed" id="15947080" target="_blank">15947080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25305253">
<a name="25305253"></a>Vukusic S, Durand-Dubief F, Benoit A, Marignier R, Frangoulis B, Confavreux C. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. <i>Mult Scler</i>. 2015;21(7):953-955. doi: 10.1177/1352458514554056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/25305253/pubmed" id="25305253" target="_blank">25305253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34139157">
<a name="34139157"></a>Wattjes MP, Ciccarelli O, Reich DS, et al; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurol</i>. 2021;20(8):653-670. doi:10.1016/S1474-4422(21)00095-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/34139157/pubmed" id="34139157" target="_blank">34139157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346529">
<a name="30346529"></a>Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of Crohn's disease using RAND/UCLA appropriateness methodology. <i>Inflamm Bowel Dis</i>. 2019;25(2):328-335. doi:10.1093/ibd/izy333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/30346529/pubmed" id="30346529" target="_blank">30346529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29982107">
<a name="29982107"></a>Yamout BI, Sahraian MA, Ayoubi NE, et al. Efficacy and safety of natalizumab extended interval dosing. <i>Multiple Sclerosis and Related Disorders</i>. 2018;24:113-116. doi: 10.1016/j.msard.2018.06.015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/29982107/pubmed" id="29982107" target="_blank">29982107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33879599">
<a name="33879599"></a>Yeh WZ, Widyastuti PA, Van der Walt A, et al; MSBase Study Group. Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. <i>Neurology</i>. 2021;96(24):e2989-e3002. doi:10.1212/WNL.0000000000012084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/33879599/pubmed" id="33879599" target="_blank">33879599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16510746">
<a name="16510746"></a>Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. <i>N Engl J Med</i>. 2006;354(9):924-933. doi:10.1056/NEJMoa054693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/natalizumab-including-biosimilars-drug-information/abstract-text/16510746/pubmed" id="16510746" target="_blank">16510746</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10252 Version 244.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
